Form 4: Aptevo Therapeutics Director Converts Restricted Stock Units to Common Shares

Aptevo Therapeutics Inc. Director Barbara Lopez Kunz converted 1 Restricted Stock Unit into common stock on July 17, 2025, following its vesting.

Summary

• Barbara Lopez Kunz, a Director of Aptevo Therapeutics Inc. (APVO), acquired 1 share of common stock on July 17, 2025.
• This acquisition resulted from the conversion of 1 Restricted Stock Unit (RSU) into common stock on a one-for-one basis.
• The RSU was part of a grant of 925 pre-split RSUs (equivalent to 1 post-split RSU) made on July 17, 2024.
• The granted RSU vested in full one year from its grant date.

Sentiment

Score: 6

Explanation: The filing reports a routine conversion of Restricted Stock Units into common stock, which is a standard part of director compensation and indicates the vesting of previously granted equity. This is a neutral to slightly positive event as it aligns director interests with shareholders, but does not signal new strategic or financial developments.

Positives

• The conversion of Restricted Stock Units into common stock indicates the vesting of previously granted equity compensation, aligning the director's interests with shareholders.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider transaction related to equity compensation and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The conversion of RSUs into common stock slightly increases the number of outstanding shares, but the impact is minimal given the small number of shares involved. It also aligns the director's interests with shareholders through direct stock ownership.

Key Dates

Keywords

Aptevo Therapeutics, APVO, SEC Form 4, Restricted Stock Units, RSU conversion, insider transaction, director compensation, equity compensation, common stock